Načítá se...
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma
BACKGROUND: Malignant pleural mesothelioma (MPM) is a very rare and highly aggressive cancer of the pleura associated in most cases with asbestos exposure. To date, no really efficient treatments are available for this pathology. Recently, it has been shown that epigenetic drugs, particularly DNA me...
Uloženo v:
| Vydáno v: | Clin Epigenetics |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6006850/ https://ncbi.nlm.nih.gov/pubmed/29946373 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-018-0517-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|